Clinical Trial Update: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC [Phase 2, Phase 3]

View source ↗

Summary

Ongoing Phase 2/Phase 3 trial evaluating INBRX-106 in combination with pembrolizumab as first-line therapy for PD-L1 CPS≥20 head and neck squamous cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• INBRX-106 (INBRX-106)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Inhibrx Biosciences, Inc | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING